ClinicalTrials.gg
Active, not recruitingNCT05185843Updated Dec 12, 2025

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

A Phase 3 interventional study of Olezarsen in Familial Chylomicronemia Syndrome, sponsored by Ionis Pharmaceuticals, Inc.. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of olezarsen (formerly known as AKCEA -APOCIII-LRX) in participants with FCS previously treated with volanesorsen.

Read the detailed description

This is a Phase 3, multi-center, open-label safety study in 24 participants with FCS, previously treated with volanesorsen. The study consists of an 8- week screening period, treatment period up to week 209 and a 13-week follow-up period. Participants enrolled will receive olezarsen every 4 weeks during the 209-week Treatment Period.

Treatment period was extended to allow participants to receive olezarsen for an additional 52 weeks for a total of a 209-week treatment period until the drug may be commercially available in the patient's country, or until the Sponsor discontinues the olezarsen development program, whichever occurs earlier.

02

Conditions studied

  • Familial Chylomicronemia Syndrome

Keywords

  • FCS
03

In context

Lead sponsor

Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Participants with FCS (clinical or genetic diagnosis) currently on or previously treated with volanesorsen (ISIS 304801)

    o Study participants in countries where Waylivra® is commercially approved and available for participants should not be deprived of the treatment option with Waylivra®. Participation in this study for such participants will only be allowed when Waylivra® was discontinued due to AEs

  2. The following concomitant medications will be allowed if dosing regimen is expected to remain constant through the end of the study (occasional or intermittent use of over-the-counter (OTC) medications will be allowed at Investigator's discretion):

    • Statins, omega-3 fatty acids (prescription and OTC), fibrates, or other lipid-lowering medications. Participants taking OTC omega-3 fatty acids should make every effort to remain on the same brand through the end of the study
    • Antidiabetic medications
    • Oral anticoagulants (e.g., dabigatran, rivaroxaban, or apixaban, and warfarin with regular clinical monitoring)
    • Tamoxifen, estrogens or progestins

Key Exclusion Criteria:

  1. Treatment with another drug (non-oligonucleotide), biological agent, or device within 4 weeks of Screening, or 5 half-lives of investigational agent, whichever is longer
  2. Concomitant medication/procedure restrictions:

    1. Systemic or anabolic steroids within 6 weeks prior to Screening and during the study unless approved by the Sponsor Medical Monitor
    2. Plasma apheresis within 4 weeks prior to Screening or planned during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Olezarsen

    Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection for up to 209 weeks.

    Drug: Olezarsen

Interventions

  • Olezarsen will be administered by SC injection.

    Also known as: ISIS 678354, AKCEA-APOCIII-LRx

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Decrease in Platelet Count by >30% or >50%, or With Platelet Count Value <50,000/cubic millimeter (mm^3)

    Time frame: Baseline to Week 209

  2. Proportion of Participants With Clinical Bleeding Events

    Time frame: Baseline to Week 209

  3. Proportion of Participants With Decrease in Estimated Glomerular Filtration Rate (eGFR) by ≥30% or ≥50%

    Time frame: Baseline to Week 209

  4. Proportion of Participants With Urine Protein/Creatinine Ratio (UPCR) ≥1000 milligram (mg)/gram (g) or with Urine/Albumin Creatinine Ratio (UACR) ≥500 mg/g

    Time frame: Baseline to Week 209

  5. Proportion of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥5 x Upper Limit of Normal (ULN)

    Time frame: Baseline to Week 209

  6. Proportion of Participants With ALT or AST ≥3 x ULN and Total Bilirubin > 2 x ULN

    Time frame: Baseline to Week 209

  7. Proportion of Participants With Total Bilirubin ≥2 mg/deciliter (dL)

    Time frame: Baseline to Week 209

Secondary outcomes

  1. Trough (Pre-Dose) Plasma Concentration of Olezarsen

    Time frame: Up to 209 weeks

  2. Post-Treatment Plasma Concentration of Olezarsen

    Time frame: Up to 209 weeks

  3. Change and Percent Change From Baseline in Fasting Triglycerides (TG)

    Time frame: Baseline to Week 209

  4. Change and Percent Change From Baseline in Fasting Apolipoprotein C-III (APOC-III)

    Time frame: Baseline to Week 209

  5. Change and Percent Change From Baseline in Fasting Very Low-Density Lipoprotein (VLDL)-C

    Time frame: Baseline to Week 209

  6. Change and Percent Change From Baseline in Fasting Chylomicron-TG

    Time frame: Baseline to Week 209

  7. Change and Percent Change From Baseline in Fasting Total Cholesterol (TC)

    Time frame: Baseline to Week 209

  8. Change and Percent Change From Baseline in Fasting Non-High-Density Lipoprotein (non-HDL)-C

    Time frame: Baseline to Week 209

  9. Change and Percent Change From Baseline in Fasting Low-Density Lipoprotein (LDL)-C

    Time frame: Baseline to Week 209

  10. Change and Percent Change From Baseline in Fasting Apoprotein B (apoB)

    Time frame: Baseline to Week 209

  11. Change and Percent Change From Baseline in Fasting Apoprotein B48 (apoB48)

    Time frame: Baseline to Week 209

  12. Change and Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL)-C

    Time frame: Baseline to Week 209

  13. Change and Percent Change From Baseline in Fasting Apoprotein A-1 (ApoA-1)

    Time frame: Baseline to Week 209

  14. Event Rate of Acute Pancreatitis

    Time frame: Up to 209 weeks

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Jun 2027, 64 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2021
First posted
Jan 11, 2022
StartActual
Feb 25, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05185843
Responsible party
Sponsor
First posted
Jan 11, 2022
Start date
Feb 25, 2022
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Dec 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olezarsen

Start the discussion